Abstract

Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model

Author(s): Baneshi Marzieh, Tyagi Deependra, Panneerselvam Ezilrani, MacKenzie Graham, Coleman Johngary, Zhang Shine X

Issue: Sep/Oct 2023 - Volume 27, Number 5

Page(s): 424-430

Download in electronic PDF format for $75
  • Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model Page 1
  • Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model Page 2
  • Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model Page 3
  • Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model Page 4
  • Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model Page 5
  • Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model Page 6
  • Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model Page 7

Abstract

To evaluate the transdermal delivery of six analgesic drugs (i.e., ketamine, gabapentin, clonidine, lidocaine, ketoprofen, and amitriptyline) that were compounded into three commercially available bases, Salt Stable LS Base, Transdermal Pain Base, and Lipoderm ActiveMax Base, the Franz finite dose model was used for an in vitro penetration study using porcine skin over 48 hours. Rapid penetration with a steady-state flux after the first 24 hours was detected in all the formulations. The present study demonstrates the successful delivery of six compounded analgesic drugs, using all of the noted bases. A high flux rate within 1 hour to 4 hours of application would correlate to effective pain relief, and the prolonged delivery over the first 24 hours would reduce the need for frequent reapplication. This can aid in pain management with the potential for enhanced pain control.

Related Keywords

  • transdermal administration
  • analgesic agents
  • analgesia
  • pain relief
  • topical preparation
  • skin penetration
  • dermal permeation
  • manufactured topical delivery vehicles
  • gabapentin
  • clonidine
  • ketamine
  • lidocaine
  • ketoprofen
  • amitriptyline
  • percutaneous absorption
  • Franz diffusion cell model

Related Categories

  • DERMATOLOGY
  • PAIN MANAGEMENT
  • PEER-REVIEWED
  • DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2003
Pg. 106-113
Veterinary Transdermal Medications: A to Z
Author(s): Davidson Gigi S
Sep/Oct 2023
Pg. 424-430
Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model
Author(s): Baneshi Marzieh, Tyagi Deependra, Panneerselvam Ezilrani, MacKenzie Graham, Coleman Johngary, Zhang Shine X
Mar/Apr 2015
Pg. 167-173
Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time
Author(s): Heustess Allie, Spigener Shuler, Sweitzer Sarah, Romero-Sandoval Alfonso, Asbill Scott
Mar/Apr 2015
Pg. 161-166
Skin Permeation and Antinociception of Compounded Topical Cyclobenzaprine Hydrochloride Formulations
Author(s): Bryson Evan, Hartman Rachel, Arnold John, Gorman Greg, Sweitzer Sarah.Asbill Scott
Jul/Aug 2004
Pg. 269-274
Current Topical Treatments in Wound Healing - Part 1
Author(s): Helmke Christopher D
Nov/Dec 2014
Pg. 512-515
In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations
Author(s): Heustess Allie, Asbill Scott, Eagerton David, Arnold John
May/Jun 2014
Pg. 256-261
Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery
Author(s): Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
Nov/Dec 2014
Pg. 504-511
Skin Penetration and Antinociception of Topical Gabapentin Formulations
Author(s): Bryson Evan, Asbill Scott, Sweitzer Sarah
May/Jun 2016
Pg. 250-256
Effect of Penetration Enhancers on the Percutaneous Delivery of Pain Management Actives
Author(s): Trimble John, Light Bob
May/Jun 2010
Pg. 182-192
Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Author(s): Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
Mar/Apr 2021
Pg. 146-155
In Vitro Permeability, Irritability, and Release Evaluation of Commonly Used Topical Diclofenac Gel Preparations (1%, 5%, and 10%)
Author(s): Kohan Hamed Gilzad, Baker David M, Sani Shabnam, Bielecki-Wilken Kathleen A, Ramirez Alfonso
Nov/Dec 2020
Pg. 446-448
NASEM Report on Compounded Topical Pain Creams
Author(s): Allen Loyd V Jr
Mar/Apr 2024
Pg. 111-116
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Author(s): Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
Mar/Apr 2015
Pg. 152-160
Transdermal Delivery of Nisoldipine: Refinement of Vehicles
Author(s): El Maghraby Gamal M, Ahmed Amal A, Osman Mohamed A
Jul/Aug 2015
Pg. 295-300
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Author(s): Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
Nov/Dec 2018
Pg. 498-503
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin
Author(s): Le Uyen Minh, Baltzley Sarah, AlGhananeem Abeer
Nov/Dec 2017
Pg. 530-535
Effect of Penetration Enhancers on the Percuaneous Delivery of Hormone Replacement Actives
Author(s): Trimble John O, Light Bob
Jul/Aug 2011
Pg. 308-315
Transdermals: The Skin as Part of a Drug Delivery System
Author(s): Allen Loyd V Jr
May/Jun 2010
Pg. 200-203
Topical Medications for Orofacial Neuropathic Pain
Author(s): Bramwell Bethany L
Jul/Aug 2001
Pg. 310-312
Wetting and/or Solubilizing Agents, Featured Excipient:
Author(s): Allen Loyd V Jr